162 related articles for article (PubMed ID: 37392249)
1. Type 2 cytokines and scleroderma interstitial lung disease.
Pellicano C; Vantaggio L; Colalillo A; Pocino K; Basile V; Marino M; Basile U; Rosato E
Clin Exp Med; 2023 Nov; 23(7):3517-3525. PubMed ID: 37392249
[TBL] [Abstract][Full Text] [Related]
2. Assessment of interstitial lung disease in systemic sclerosis using the quantitative CT algorithm CALIPER.
Ferrazza AM; Gigante A; Gasperini ML; Ammendola RM; Paone G; Carbone I; Rosato E
Clin Rheumatol; 2020 May; 39(5):1537-1542. PubMed ID: 31940114
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
4. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
De Lauretis A; Sestini P; Pantelidis P; Hoyles R; Hansell DM; Goh NS; Zappala CJ; Visca D; Maher TM; Denton CP; Ong VH; Abraham DJ; Kelleher P; Hector L; Wells AU; Renzoni EA
J Rheumatol; 2013 Apr; 40(4):435-46. PubMed ID: 23378460
[TBL] [Abstract][Full Text] [Related]
7. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
[TBL] [Abstract][Full Text] [Related]
8. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
[TBL] [Abstract][Full Text] [Related]
9. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
Yamakawa H; Takemura T; Iwasawa T; Yamanaka Y; Ikeda S; Sekine A; Kitamura H; Baba T; Iso S; Okudela K; Kuwano K; Ogura T
BMC Pulm Med; 2018 Jan; 18(1):25. PubMed ID: 29382307
[TBL] [Abstract][Full Text] [Related]
10. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
11. Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation.
Mattoo H; Bangari DS; Cummings S; Humulock Z; Habiel D; Xu EY; Pate N; Resnick R; Savova V; Qian G; Beil C; Rao E; Nestle FO; Bryce PJ; Subramaniam A
Am J Respir Cell Mol Biol; 2023 Oct; 69(4):404-421. PubMed ID: 37369139
[TBL] [Abstract][Full Text] [Related]
12. Worsening of esophageal dilatation is associated with increase in a high-resolution computed tomography (HRCT) score in early systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Wangkaew S; Losuriya P; Euathrongchit J
Clin Rheumatol; 2021 Mar; 40(3):955-963. PubMed ID: 32803568
[TBL] [Abstract][Full Text] [Related]
13. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
[TBL] [Abstract][Full Text] [Related]
14. Novel Assessment of Interstitial Lung Disease Using the "Computer-Aided Lung Informatics for Pathology Evaluation and Rating" (CALIPER) Software System in Idiopathic Inflammatory Myopathies.
Ungprasert P; Wilton KM; Ernste FC; Kalra S; Crowson CS; Rajagopalan S; Bartholmai BJ
Lung; 2017 Oct; 195(5):545-552. PubMed ID: 28688028
[TBL] [Abstract][Full Text] [Related]
15. Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study.
Richardson C; Agrawal R; Lee J; Almagor O; Nelson R; Varga J; Cuttica MJ; Dematte JD; Chang RW; Hinchcliff ME
Semin Arthritis Rheum; 2016 Aug; 46(1):109-14. PubMed ID: 27033049
[TBL] [Abstract][Full Text] [Related]
16. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Interstitial Lung Disease in Egyptian Patients with Systemic Sclerosis: Relation to Disease Parameters.
Abdelati AA; Deghady AA; Abdelhady AM; Bastawy RA; Shaaban A
Curr Rheumatol Rev; 2023; 19(2):189-196. PubMed ID: 35984025
[TBL] [Abstract][Full Text] [Related]
19. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
Schmidt K; Martinez-Gamboa L; Meier S; Witt C; Meisel C; Hanitsch LG; Becker MO; Huscher D; Burmester GR; Riemekasten G
Arthritis Res Ther; 2009; 11(4):R111. PubMed ID: 19615053
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.
Kuzumi A; Yoshizaki A; Toyama S; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Asano Y; Sato S
J Dermatol; 2018 Oct; 45(10):1216-1220. PubMed ID: 30004593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
